Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
InhaleRx Limited ( (AU:NX1) ) just unveiled an announcement.
Nexalis Therapeutics Ltd has applied to the ASX for quotation of 780,000 new ordinary fully paid shares under code NX1, with an issue date of 23 February 2026. The additional securities, which arise from previously announced transactions, will expand the company’s quoted share base and may marginally affect ownership dilution and liquidity for existing investors.
The move signals ongoing capital-related activity at Nexalis Therapeutics, reflecting the company’s continued use of equity markets to support its operations and strategic initiatives. While the announcement is largely procedural, the increase in quoted securities helps clarify the company’s evolving capital structure for stakeholders and the broader market.
The most recent analyst rating on (AU:NX1) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on InhaleRx Limited stock, see the AU:NX1 Stock Forecast page.
More about InhaleRx Limited
Nexalis Therapeutics Ltd is a biotechnology company listed on the ASX under the ticker NX1. The company operates in the therapeutics sector, focusing on the development of medical treatments, although the specific products or therapeutic areas are not detailed in the filing.
Average Trading Volume: 272,864
Technical Sentiment Signal: Sell
Current Market Cap: A$7.32M
For detailed information about NX1 stock, go to TipRanks’ Stock Analysis page.